Do plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure?
Circulating levels of miRNAs are responsive to therapeutic interventions and change during the progression of hypertension-induced heart disease.
The high probability of comorbid chronic conditions as well as higher disability among those with sleep problems makes this an important area of research.